Vivo Bio Tech Reports Q4 Loss, Faces Statutory Dues Scrutiny

Vivo Bio Tech Ltd. reported a standalone net loss of ₹5.44 crore for the fourth quarter ended March 31, 2026. This marks a significant downturn from a profit of ₹1.26 crore in the preceding quarter.

Consolidated net loss for the quarter stood at ₹5.16 crore.

Reader Takeaway: Operational pressure evident in quarterly loss; restructuring plans offer strategic pivot.

What just happened

Vivo Bio Tech has announced its audited financial results for the fourth quarter and year ended March 31, 2026. The company recorded a standalone net loss of ₹5.44 crore, compared to a profit of ₹1.26 crore in the December 2025 quarter. Revenue from operations for the quarter was ₹13.77 crore.

The company also disclosed outstanding statutory dues amounting to ₹4.19 crore as of March 31, 2026. These dues include ₹1.90 crore in Self-Assessment Tax, ₹1.51 crore in TDS, and ₹0.61 crore in Provident Fund, among others.

Why this matters

The shift to a quarterly loss and the auditor's emphasis on outstanding statutory dues are key concerns for investors. The significant amount of pending dues, particularly TDS and Self-Assessment Tax, raises questions about the company's liquidity management and compliance. The planned restructuring via a Scheme of Arrangement or Amalgamation suggests management is seeking strategic options to address these challenges or unlock value.

The backstory

Vivo Bio Tech, a company operating in the biotechnology sector, has been navigating market dynamics. While the immediate quarterly results show a profit decline, the company's strategic moves, such as exploring amalgamation, indicate a forward-looking approach to business evolution.

What changes now

The board's approval to appoint a consultant for a Scheme of Arrangement or Amalgamation signals the initiation of a significant corporate restructuring process. Investors will need to closely follow future announcements for details on the proposed transaction, which could involve mergers, acquisitions, or demergers. The re-appointment of Mr. Kalyan Ram Mangipudi as Whole-time Director for five years also ensures leadership continuity.

Risks to watch

The primary risk lies in the company's ability to manage its outstanding statutory dues and the potential financial implications if these are not resolved promptly. The auditor's 'Emphasis of Matter' highlights this as a key concern. Furthermore, the success and impact of the proposed Scheme of Arrangement will be crucial for future performance.

Peer comparison

While specific financial data for direct peers was not provided in the filing, companies in the biotech sector often face scrutiny regarding R&D investment, regulatory approvals, and financial sustainability. Vivo Bio Tech's current situation highlights the importance of robust financial health and compliance, which are critical for growth and investor confidence in this industry.

Context metrics (time-bound)

• Q4 FY26 Standalone Net Loss: ₹5.44 crore
• Q3 FY26 Standalone Net Profit: ₹1.26 crore
• Total Outstanding Statutory Dues (as of March 31, 2026): ₹4.19 crore
• Re-appointment Period for Whole-time Director: 5 years (2026-2031)

What to track next

Investors should keenly watch for further details regarding the proposed Scheme of Arrangement or Amalgamation, including the appointment of the consultant and the nature of the transaction. Monitoring the company's progress in addressing its statutory dues and any updates on related party transactions will also be important.